Novo Nordisk A/S (NVO)
Salud / Farmacéutica
Novo Nordisk trades It trades close to intrinsic value, far from the required margin of safety. after a price reset the company itself triggered: it is cutting Wegovy's list price by roughly 50% starting in 2027 and guides 2026 to slightly negative territory, while obesity volume grows 19% at constant exchange rates. At 13× on earnings, the market is pricing the realized price it is losing and not crediting the volume it is gaining; the estimated return is +9% annually and the verdict is Fairly valued.
- Price
- $48.19
- Intrinsic value (5y, base)
- $61
- Total annual return (5y)
- 8.7%
- Status (nominal)
- Fairly valued
- Margin of safety
- +17%
The essentials
- 2026 guidance was raised twice: from the -4% to -12% range in May to 0% to -6% at constant exchange rates on August 4, on higher expected sales of GLP-1 products.
- Volume is growing while price resets: adjusted obesity sales up 19% at constant exchange rates in the first half of 2026, against a roughly 50% cut to Wegovy's list price starting in 2027.
- Capex declines for the first time in the cycle: DKK 55,000 million guided for 2026 versus DKK 60,140 million in 2025, with the company stating that investment declines in subsequent years.
- Semaglutide's compound patent in the United States expires in 2032, just past the five-year horizon, and there is already loss of exclusivity in certain international markets.
Intrinsic value — two valuation methods
Total return at 5 years: 66.6%/year = 51.8% appreciation + 14.8% dividend. The target price ($388) is ex-dividend; the $68 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $541 · Multiples $371) exceeds the market price ($48).
Pillars of the analysis
The verdict — today vs 5 years
Today — with margin of safety: at $48 trades ~87.0% below its value discounted to today (~$371) — the wide discount we require (≥38%, equivalent to a ~15% annual return); the risk is covered by the margin, not the rate.
At 5 years — Muy infravalorado: the target price ($388) plus dividends yield above the required average return (10%) — the business compounds.
The bridge: the return at 5 years comfortably exceeds the risk-free rate (4.5%) — and the discount reaches the required margin of safety.
Thesis
The business
A branded pharmaceutical with exceptional return on capital, a wide but eroding moat, and a franchise concentrated in a single molecule. The quality of the business is not in question: operating margins above 40% and a co-leading position in a therapeutic market that keeps expanding. What is in question is how much of that margin survives the U.S. price reset and how much value remains after 2032.
The valuation
Valued on P/E over normalized net income, in Danish kroner, with the conversion to dollars in the last line of the bridge. Year 1 is anchored to current guidance rather than to the trend; the exit multiple comes from the pharmaceutical archetype's band, positioned below center on the patent expiration that falls just past the horizon. The result is a five-year value implying +67% annually at market price, with +52% from appreciation and +15% from dividends.
The margin of safety
There is a margin of safety: the market's perception is meaningfully worse than reality. The price of $48 against the value brought to today puts the verdict at Very undervalued. The scale of demand is the usual one: 4% to preserve nominal capital, 10% to match the average return on stocks, and 15% for a great investment. The adverse scenario, which assumes the price cut is not offset by volume, yields +67% annually; the favorable one, +67%.
What to watch
The test is realized price per prescription starting in the first quarter of 2027, when the list-price cut and Medicare negotiation take effect. If incremental volume from the oral Wegovy presentation and from international markets does not offset the drop in per-unit revenue, the thesis breaks on the margin side. The second indicator is capex: the company guided a decline to DKK 55,000 million in 2026 and a further decline after that; if it instead rises again without sales keeping pace, the return on incremental capital deteriorates.
Educational / informational. Does not constitute investment advice.